Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Posterior Uveitis Overview | 6 | 1 |
| Therapeutics Development | 7 | 1 |
| Pipeline Products for Posterior Uveitis Overview | 7 | 1 |
| Posterior Uveitis Therapeutics under Development by Companies | 8 | 1 |
| Posterior Uveitis Pipeline Products Glance | 9 | 3 |
| Late Stage Products | 9 | 1 |
| Clinical Stage Products | 10 | 1 |
| Early Stage Products | 11 | 1 |
| Posterior Uveitis Products under Development by Companies | 12 | 1 |
| Posterior Uveitis Companies Involved in Therapeutics Development | 13 | 7 |
| Aciont Inc. | 13 | 1 |
| Neuroptis Biotech | 14 | 1 |
| Oculis ehf | 15 | 1 |
| pSivida Corp. | 16 | 1 |
| Regeneron Pharmaceuticals Inc | 17 | 1 |
| Sandoz International GmbH | 18 | 1 |
| Santen Pharmaceutical Co., Ltd. | 19 | 1 |
| Posterior Uveitis Therapeutics Assessment | 20 | 9 |
| Assessment by Monotherapy Products | 20 | 1 |
| Assessment by Target | 21 | 2 |
| Assessment by Mechanism of Action | 23 | 2 |
| Assessment by Route of Administration | 25 | 2 |
| Assessment by Molecule Type | 27 | 2 |
| Drug Profiles | 29 | 23 |
| adalimumab biosimilar Drug Profile | 29 | 1 |
| dexamethasone acetate Drug Profile | 30 | 1 |
| dexamethasone sodium phosphate Drug Profile | 31 | 2 |
| EYS-606 Drug Profile | 33 | 1 |
| fluocinolone acetonide SR Drug Profile | 34 | 9 |
| NOP-3 Drug Profile | 43 | 1 |
| sarilumab Drug Profile | 44 | 5 |
| sirolimus Drug Profile | 49 | 3 |
| Posterior Uveitis Dormant Projects | 52 | 1 |
| Posterior Uveitis Discontinued Products | 53 | 1 |
| Posterior Uveitis Product Development Milestones | 54 | 10 |
| Featured News &Press Releases | 54 | 1 |
| Oct 04, 2016: Phase 3 trial of Medidur in Posterior Segment Uveitis Meets Enrollment Target | 54 | 1 |
| Aug 15, 2016: Topline Results from First Phase 3 Trial of pSividas Medidur Presented at ASRS Annual Meeting | 54 | 1 |
| Aug 09, 2016: Primary Endpoint Met in pSivida's Utilization Study of New Medidur Inserter with Smaller Diameter Needle | 55 | 1 |
| Jul 27, 2016: pSivida's Medidur Maintains Same High Statistical Significance in Primary Endpoint through 12 Months in First Phase 3 Trial (p Less Than 0.00000001) | 55 | 1 |
| Jul 14, 2016: Investigator-Sponsored Phase 2 Study Results Show pSivida s Medidur Fully Controlled Uveitis for Two Years with No Recurrence of Disease While Visual Acuity Continued to Improve | 56 | 1 |
| May 02, 2016: pSividas Medidur for Posterior Uveitis Granted Orphan Drug Designation in Europe | 57 | 1 |
| Mar 15, 2016: Additional Favorable Six-Month Safety Results for pSividas Medidur for Posterior Uveitis | 58 | 1 |
| Dec 28, 2015: pSivida Plans Medidur EU Marketing Approval Application Based on Single Phase 3 Clinical Trial | 58 | 1 |
| Dec 22, 2015: pSivida Medidur Meets Primary Efficacy Endpoint in Phase 3 Trial: High Statistical Significance in Prevention of Recurrence of Posterior Uveitis | 59 | 2 |
| Sep 28, 2015: pSivida Announces NDA for Medidur Now Planned Using Six-Month Efficacy Data from Both Phase III Trials; FDA Concurs | 61 | 1 |
| May 19, 2015: pSivida Reports Positive IOP Safety Data in Phase III Trial of Medidur for Posterior Uveitis | 61 | 1 |
| Mar 26, 2015: pSivida Completes Targeted Enrollment of Phase III Trial of Medidur for Posterior Uveitis | 62 | 1 |
| Apr 15, 2013: Aciont To Present at ARVO 2013 Annual Meeting | 63 | 1 |
| Appendix | 64 | 2 |
| Methodology | 64 | 1 |
| Coverage | 64 | 1 |
| Secondary Research | 64 | 1 |
| Primary Research | 64 | 1 |
| Expert Panel Validation | 64 | 1 |
| Contact Us | 64 | 1 |
| Disclaimer | 65 | 1 |